Article
Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin.
Antimicrobial agents and chemotherapy - 1 Jul 2000
Bachoual R, Dubreuil L, Soussy C J, Tankovic J
Abstract excerpt
We determined whether gyrA mutations were present in fluoroquinolone-resistant laboratory mutants derived from the Bacteroides fragilis reference strain ATCC 25285 and in clinical isolates of B. fragilis. The two first-step mutants selected on ciprofloxacin (CIP) were devoid of gyrA mutations, whereas two of the three CIP-selected second-step mutants studied presented the same gyrA mutation leading to a Ser82Phe...
Topics
- Anti-Infective Agents
- Bacteroides fragilis
- Ciprofloxacin
- DNA Gyrase
- DNA Topoisomerases, Type II
- Drug Resistance, Microbial
- Fluoroquinolones
- Humans
- Microbial Sensitivity Tests
- Mutation
- Naphthyridines
- Norfloxacin